MSFP
KNSA icon

Mark Sheptoff Financial Planning’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$936K Buy
16,500
+150
+0.9% +$6.64K 0.5% 38
2025
Q4 		$674K Buy
16,350
+250
+2% +$10K 0.32% 50
2025
Q3 		$625K Buy
+16,100
New +$523K 0.3% 49

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Mark Sheptoff Financial Planning's KNSA Position: Q1 2026 in Review

Mark Sheptoff Financial Planning increased its Kiniksa Pharmaceuticals (KNSA) stake by 0.92% in Q1 2026, buying an estimated $6.64K and bringing the position to 16,500 shares worth $936K. The position accounts for 0.5% of the portfolio, ranked #38.

Mark Sheptoff Financial Planning first reported a position in KNSA in Q3 2025 and has held it in 3 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Mark Sheptoff Financial Planning held 16,500 shares of Kiniksa Pharmaceuticals worth $936K as of Q1 2026.
  • Mark Sheptoff Financial Planning bought 150 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $6.64K.
  • Kiniksa Pharmaceuticals made up 0.5% of Mark Sheptoff Financial Planning's portfolio in Q1 2026, its #38 holding.
  • Mark Sheptoff Financial Planning first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Mark Sheptoff Financial Planning's 13F filing for Q1 2026, filed 11 May 2026.